新华财经北京12月30日电近日，吉因加科技（绍兴）股份有限公司（以下简称"吉因加科技"）向港交所 主板提交上市申请，其联席保荐人为建银国际、民银资本。 吉因加科技主要业务包括精准诊断、药物研发赋能以及临床科研与转化解决方案。成立至今，公司已获 得多轮融资，投资方包括华大基因、爱尔医疗、达晨财智、纪源资本等。 此次赴港IPO，吉因加科技拟募资用于提升研发能力及扩展产品组合等。 业绩方面，2022年至2024年，吉因加科技收入分别为18.15亿元、4.73亿元、5.57亿元，期内利润分别为 3.72亿元、5412.7万元、-4.24亿元。 公司于2022年至2023年间收入下滑，主要是COVID-19疫情结束后逐步终止COVID-19核酸检测服务所 致。 2025年上半年，吉因加科技收入为2.85亿元，同比增长12.69%；期内利润为-4.14亿元，较去年同期亏损 幅度扩大。其中一个重要原因为以公允价值计量且其变动计入损益的金融负债为-3.62亿元。 供应商依赖度较高 收入结构方面，精准诊断解决方案是吉加因科技核心业务，近年来收入占比超过70%。该业务主要包括 体外诊断（IVD）产品销售及临床实验室检测服务。20 ...

在年会现场，麦迪科技首席技术官范小锋围绕产品定位与应用方向进行了详细介绍，他在会上强调，优 麦康养陪伴机器人采用全栈式自主可控研发路径，涵盖本体结构、运动控制、感知交互、AI对话与系 统平台等核心环节，面向真实康养场景进行设计与迭代。据现场反馈，机器人的外形高度仿真，皮肤纹 理细腻。范小锋指出："冰冷的机器无法做到情感陪伴，它没有温度，所以我们选择市面上成熟的仿真 人本体厂家合作，以类肤材质和柔性触感，营造真实的情感陪伴。" 产品发布的同时，麦迪科技正式启动优麦康养陪伴机器人001号CR认证。据了解，CR认证属于中国机 器人领域的最高标准之一，也是目前全国范围内康养陪伴机器人单品类的唯一认证。公司指出，该认证 的启动，意味着优麦机器人在安全性、可靠性、功能适配性等方面全面对标国家要求与康养场景需求， 是行业发展的重要里程碑。上海机器人产研院院长郑军奇、副院长周梅杰与麦迪科技副总裁吴镝、首席 技术官范小锋共同参与了认证启动仪式。 12月28日，麦迪科技（603990）(603990.SH)二十周年年会在苏州凯宾斯基酒店隆重举行，以"医疗科技 二十载，具身智能启新程"为主题，正式开启面向未来的新征程。年会现场，麦 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report emphasizes the potential of brain-computer interface (BCI) technology and AI medical applications, predicting significant developments in 2026. It suggests focusing on innovative drug stocks and medical technology themes, particularly in the context of an aging population and the recovery of consumer spending in healthcare [3][5][42]. Summary by Sections 1. Policy Catalysts and BCI Application Potential - The brain-computer interface (BCI) technology is highlighted as a key area of growth, with the market expected to reach approximately $2.62 billion by 2024 and grow to $12.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2034 [12][18]. - The medical sector is projected to account for about 46% of the BCI application market in 2024, focusing on areas such as neurological rehabilitation and sensory diagnostics [13][18]. 2. Industry Perspective: Innovation and Global Expansion - The pharmaceutical index has shown a decline of 0.18% from December 22 to December 26, 2025, with a year-to-date increase of 14.29%. The report notes a significant number of stocks experiencing both gains and losses during this period [25][30]. - The report identifies key stocks to watch, including innovative drug companies and those involved in the BCI and AI medical sectors, suggesting a focus on companies like Heng Rui Medicine, Zai Lab, and others [42][45]. 3. Investment Opportunities - The report suggests that the pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs leading the way. It highlights the increasing global competitiveness of Chinese pharmaceutical companies and their growing capabilities in international markets [41][42]. - Specific recommendations include focusing on innovative drugs, medical devices, and companies involved in the BCI sector, with a particular emphasis on those with strong fundamentals and potential for recovery in 2026 [42][44].

每日经济新闻 （责任编辑：董萍萍 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 中信建投指出，医疗器械行业长期投资机会来自创新、出海和并购整合，板块的创新性和国际化能 力得到认可，估值正在重估。近期国家药监局发布优先审批高端医疗器械目录，脑机接口、超高场强核 磁、手术机器人等有望受益。短期来看，Q4和26年业绩改善个股存在业绩估值修复机会，部分公司将 于1月份发布年报业绩预告，建议关注前瞻超预期或低预期情况。长期来看，医疗器械行业投资机会来 自创新、出海和并购整合，板块的创新和国际化能力得到认可，估值正在重构。建议持续关注市场空间 大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等 主题方向的投资机会。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅达20%，该指数聚焦 于创新医药领域，从生物制药、化学制药、中药及医疗服务等 ...

Core Viewpoint - The report highlights that Health 160 (2656.HK), a leading digital healthcare platform in China, is approaching a profitability inflection point, driven by its unique resource endowment and value reassessment, with a "Buy" rating and a target price of HKD 90.54 [1] Group 1: Company Overview - Health 160 is recognized as a top digital healthcare service platform in China, with over 18 years of industry experience, leading in key resource metrics such as appointment volume and the number of partnered medical institutions and healthcare professionals [1] - The company has established strong "resource + user" dual barriers, positioning itself favorably in the market [1] Group 2: Financial Performance - The company has shown clear signs of a performance inflection point, with revenue returning to a growth trajectory and adjusted net losses significantly narrowing, indicating a path towards profitability [1] - Revenue projections for 2025-2027 are estimated at CNY 674 million, CNY 775 million, and CNY 930 million, with growth rates of 8%, 15%, and 20% respectively [2] - Net profit forecasts for the same period are CNY 12 million, CNY 36 million, and CNY 90 million, reflecting a gradual improvement in financial health [2] Group 3: Business Model and Growth Drivers - The business operates on a dual-driven model consisting of "pharmaceutical product distribution" and "digital health services," supported by a localized network covering over 260 cities [1] - The company is benefiting from the high growth potential of the digital healthcare industry, with a unique platform value and a clear path to profitability, suggesting a critical value reassessment from "loss reduction" to "profitability" [1]

Core Viewpoint - The company, Desheng Technology, is actively involved in the digital RMB and AI healthcare sectors, showcasing its technological capabilities and strategic partnerships to enhance its service offerings and market presence [1][2]. Group 1: Digital RMB Initiatives - The company is participating in the Beijing Minsheng Card project, which involves the first digital RMB hardware wallet [1]. - Desheng Technology has signed cooperation agreements with Postal Savings Bank and Agricultural Credit Interconnection to explore digital RMB applications [1]. - The company aims to implement digital RMB in social security cards and government subsidy distribution, indicating its readiness for practical applications in this area [1]. Group 2: AI Healthcare Developments - The company is integrating its "no-fee payment" platform into hospital HIS systems to streamline payment processes [1]. - Desheng Technology's AI medical products are being deployed in various provinces, including Guangdong, Anhui, and Guizhou, focusing on intelligent diagnosis and management of chronic diseases [1]. - The company has received recognition for its "no-fee payment" platform, which is now implemented in all top-tier hospitals in Guangzhou [1]. Group 3: Financial and Operational Updates - On December 26, the company reported a stock price of 9.41 yuan, with a trading volume of 41,700 shares and a turnover of 39.41 million yuan [1]. - The company plans to conclude four fundraising projects and allocate 609,600 yuan of surplus funds to enhance its working capital [2][3]. - The net outflow of main funds was 3.306 million yuan, while retail investors saw a net inflow of 4.7778 million yuan on the same day [2][3].

Core Insights - The AI medical application "Ant Financial Afo" has rapidly gained popularity, reaching the third position in Apple's free app rankings shortly after its launch on December 15, indicating a strong market demand for AI medical applications [1] - The AI medical sector is entering a critical phase of commercialization, driven by national strategies and market needs, with significant participation from medical institutions and the deployment of large models across various departments [1] Policy and Infrastructure - National policies are continuously improving to support AI in healthcare, with specific guidelines outlining 24 key applications across eight areas, including clinical diagnosis and patient services [2] - The National Medical Insurance Administration has included "AI-assisted diagnosis" in the pathology diagnosis expansion items, paving the way for its inclusion in the medical insurance reimbursement system [2] - Local governments are also implementing supportive measures, such as Zhejiang's action plan to establish a national AI medical application base by 2027, focusing on the "Anzhener" medical model [2] Industry Development - The establishment of the Zhejiang AI Medical Application Pilot Base is accelerating infrastructure development, providing a comprehensive platform for model research, validation, and application promotion [3] - This base aims to lower innovation barriers and technical validation costs, fostering a cluster effect in the industry and enhancing the standardization and intelligence of the healthcare sector [3] Corporate Strategies - Various companies are actively entering the AI medical field, leveraging favorable policies and a mature market environment [4] - Zhejiang Heren Technology has developed a product matrix centered around its AI application development platform, including AI clinical workstations and mobile diagnostic assistants to improve efficiency [4] - Shanghai RunDa Medical Technology is focusing on digital transformation in healthcare, developing over 20 AI products across clinical assistance, patient management, and research innovation [4] - Companies are also targeting high-barrier niche markets, such as Jiangsu Kangzhong Digital Medical Technology, which showcased its low-dose imaging solution at a major radiology conference [4] Future Outlook - The AI medical sector has significant growth potential, with AI technologies providing scientific support across various healthcare processes, including disease prevention and personalized treatment [5] - Companies are advised to focus on high-barrier segments requiring certification and develop low-code AI tools for grassroots medical institutions to capture long-tail markets [5] - Emphasizing algorithm transparency and compliance with medical regulations while integrating with regional healthcare data platforms is crucial for innovation [5]

Core Viewpoint - The article highlights the increasing concern regarding in-flight medical emergencies, particularly following a recent incident involving a passenger death on a Lufthansa flight, emphasizing the need for improved medical support and equipment on aircraft [2][4][5]. Summary by Sections In-Flight Medical Emergencies - It is reported that globally, a medical emergency occurs on a passenger aircraft every 12 minutes, with approximately 70% of these incidents happening on intercontinental flights [6]. - The overall incidence rate of in-flight medical emergencies is low, estimated at 8 to 50 per 1 million passengers, while the probability of an unscheduled landing due to such emergencies is 1 in 1 million, and the death rate is about 1 in 2 million passengers [6]. Causes and Statistics - The majority of medical emergencies are triggered by cardiovascular symptoms, followed by neurological and gastrointestinal issues [7]. - Over 80% of incidents involve medical professionals on board, and more than 35% of emergencies concern passengers aged 55 and older, with the peak age range being 56 to 65 years [6]. Medical Equipment and Training - Aircraft are equipped with various medical supplies, including doctor’s kits, automated external defibrillators (AEDs), and multiple first aid kits, with additional medical supplies available on long-haul flights [7]. - Crew members receive training in first aid, including CPR and AED usage, to handle potential emergencies [8]. Challenges in Emergency Response - Experts indicate that high-altitude medical emergencies pose significant challenges, particularly in diagnosing and treating complex acute cardiac conditions due to environmental constraints and limited medical supplies [10]. - There is a call for better medical equipment, such as electronic blood pressure monitors and portable ultrasound devices, to enhance emergency response capabilities on flights [10]. Legal and Ethical Considerations - The legal implications and responsibilities surrounding in-flight medical assistance can deter medical professionals from providing help, as they may face requests for personal information and credentials after offering aid [10].

Core Insights - Ant Group's AI health app, Antifufu, quickly rose to the top three in the Apple App Store, achieving over 15 million monthly active users, making it the largest health management AI app in China [1] - The app addresses two major pain points in internet healthcare: low-frequency medical consultations and uneven resource distribution, transforming infrequent medical inquiries into frequent health companionship, thus democratizing access to quality medical resources [1] - The popularity of Antifufu is not an isolated incident; it empowers the industry chain with three core investment dimensions: AI + home smart devices, AI + offline health check-ups, and AI + pharmaceutical retail and services [1] - This indicates that AI healthcare has transitioned from laboratory research to industrial application, and investors should focus on companies that can deeply integrate with AI and possess core advantages [1] - The success of Antifufu may mark the beginning of a transformation in AI healthcare [1] Investment Dimensions - The three core investment dimensions identified are: 1. AI + home smart devices 2. AI + offline health check-ups 3. AI + pharmaceutical retail and services [1] - Companies that align with these dimensions and have strong core advantages are expected to benefit from the growth of the AI healthcare sector [1][3] - The AI healthcare sector is moving from experimental phases to practical applications, indicating a significant investment opportunity in this core market [3]

衡宇 发自 凹非寺 量子位 | 公众号 QbitAI "做AI医疗，最不应该做的就是和正常医生走得太近。" 百川智能创始人、CEO王小川 把这句话抛出来的时候，台下先是愣了一下，紧接着有人笑了。 这是王小川在 清华大学百川楼 启用后，在百川楼一场 围绕AI医疗展开的圆桌对谈 中，给出的唯一一条建议。 与他同台的两位嘉宾，分别站在AI与医疗领域的另外两个关键位置上： 一位是长期从事人工智能与认知智能研究的学者， 清华大学人工智能研究院常务副院长孙茂松 ；另一位是身处真实医疗体系核心的一线管理 者， 中国医学科学院肿瘤医院副院长李宁 。 AI创业者、研究学者、医疗/医学从业者，共三种视角。 在当下AI医疗讨论中，几乎是最典型、也最难同时坐在一张桌子上的三种视角。 在AGI加速到来的背景下，医疗被普遍认为是"最复杂、也最有可能通向通用智能"的终极场景之一。 是以，人们围绕AI医疗的讨论已经不只局限在技术本身，谈论话题的人也不只有来自AI和医疗领域的从业者。 因为它的未来会和每一个人息息相关。 在这场持续40余分钟的圆桌讨论中，三位嘉宾分别从 评测、责任、决策权、临床思维、算法边界 等现实问题出发，有共识，也有分歧； ...